Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita

Cochrane Database of Systematic Reviews

Volumn 2003, Issue 1, 2003, Pages

  Kirtschig, Gudula ^a   Murrell, Dedee F ^b   Wojnarowska, Fenella ^c   Khumalo, Nonhlanhla P ^d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DAPSONE; FLUOCINONIDE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN; MINOCYCLINE; MITOMYCIN; MYCOPHENOLATE MOFETIL; PREDNISOLONE; PREDNISONE; STEROID; SULFAMETHOXYPYRIDAZINE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

AGRANULOCYTOSIS; ALOPECIA; ANEMIA; ANTIGEN ANTIBODY REACTION; BASEMENT MEMBRANE; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE COURSE; DRESS SYNDROME; DRUG EFFICACY; DRUG SAFETY; EPIDERMOLYSIS BULLOSA ACQUISITA; GASTROINTESTINAL DISEASE; HAIR LOSS; HEMATURIA; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE; KERATINIZATION; LEUKOPENIA; METHEMOGLOBINEMIA; MUCOSA; MUCOUS MEMBRANE PEMPHIGOID; MYOPATHY; NAUSEA; NEUROPATHY; OSTEOPOROSIS; PANCYTOPENIA; PATHOGENESIS; PEPTIC ULCER; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SYSTEMATIC REVIEW; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

CYCLOPHOSPHAMIDE; EPIDERMOLYSIS BULLOSA ACQUISITA; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; RANDOMIZED CONTROLLED TRIALS;

EID: 0037264907     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004056     Document Type: Review

References (65)

1. Foster, Stephen. Cicatricial pemphigoid. Transactions of the American Ophthalmological Society 1986;84:527-663 (pp 619-38). [MEDLINE: 3804625]
2. Foster, Stephen. Cicatricial Pemphigoid. Transactions of the American Ophthalmological Society 1986;84:527-663 (pp 638-40). [MEDLINE: 3804625]
3. Arpey CJ, Elewski BE, Moritz DK, Gammon WR. Childhood epidermolysis bullosa acquisita. Journal of the American Academy of Dermatology 1991;24:706-14.
4. Axt M, Wever S, Baier G, Bogdan S, Hashimoto T, Bröcker EB, et al. Cicatricial pemphigoid--a therapeutic problem. Hautarzt 1995;46(9):620-7.
5. Bialasiewicz AA, Forster W, Radig H, Hüttenbrink KB, Grewe S, Busse H. Syngeneic transplantation of nasal mucosa and azathioprine medication for therapy of cicatricial ocular mucous membrane pemphigoid. Study of 9 patients with 11 eyes. Ophthalmologe 1994;91(2):244-50.
6. Callot-Mellot C, Bodemer C, Caux F, Bourgault-Villada I, Fraitag S, Goudié G, et al. Epidermolysis bullosa acquisita in childhood. Archives of Dermatology 1997;133(9):1122-6.
7. Carbone M, Carrozzo M, Castellano S, Conrotto D, Broccoletti R, Gandolfo S. Systemic corticosteroid therapy of oral vesiculoerosive diseases (OVED). An open trial. Minerva Stomatologica 1998;47(10):479-87.
8. Carrozzo M, Carbone M, Broccoletti R, Garzino-Demo P, Gandolfo S. Therapeutic management of mucous membrane pemphigoid. Report of 11 cases:. Minerva Stomatologica 1997;46(10):553-9.
9. Cunningham BB, Kirchmann TT, Woodley D. Colchicine for epidermolysis bullosa acquisita. Journal of the American Academy of Dermatology 1996;34(5 Pt 1):781-4.
10. Donnenfeld ED, Perry HD, Wallerstein A, Caronia RM, Kanellopoulos AJ, Sforza PD, et al. Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid. Ophthalmology 1999;106(1):72-9.
11. Edwards S, Wakelin SH, Wojnarowska F, Marsden RA, Kirtschig G, Bhogal B, et al. Bullous pemphigoid and epidermolysis bullosa acquisita: presentation, prognosis, and immunopathology in 11 children. Pediatric Dermatology 1998;15(3):184-90.
12. Kirtschig G, Wojnarowska F, Marsden RA, Edwards S, Bhogal B, Black MM. Acquired bullous diseases of childhood: re-evaluation of diagnosis by indirect immunofluorescence examination on 1 M NaCl split skin and immunoblotting. British Journal of Dermatology 1994;130(5):610-6.
13. Elder MJ, Lightman S, Dart JK. Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. The British Journal of Ophthalmology 1995;79(3):264-6.
14. Elder MJ, Leonard J, Dart JK. Sulphapyridine -a new agent for the treatment of ocular cicatricial pemphigoid. The British Journal of Ophthalmology 1996;80(6):549-52.
15. Fern AI, Jay JL, Young H, MacKie R. Dapsone therapy for the acute inflammatory phase of ocular pemphigoid. The British Journal of Ophthalmology 1992;76(6):332-5.
16. Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology 1982;89(4):340-53.
17. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999;106(11):2136-43.
18. Francis IC, McCluskey PJ, Walls RS, Wakefield D, Brewer JM. Ocular cicatricial pemphigoid. Australian and New Zealand Journal Ophthalmology 1990;18(2):143-50.
19. Gillies M, Francis I, McCluskey P, Wakefield D. Local interferon alfa-2b for ocular cicatricial pemphigoid [letter]. The British Journal of Ophthalmology 1996;80(10):927.
20. Gonzalez-Moles MA, Ruiz-Avila I, Rodriguez-Archilla A, Morales-Garcia P, Mesa-Aguado F, Bascones-Martinez A, et al. Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays. Oral Surgery Oral Medicine Oral Pathology Oral Radiology & Endodontics 2003;95:688-92.
21. Gordon KB. Epidermolysis bullosa acquisita: oral methoxsalen (8-MOP) is administered 90 minutes prior to leukapheresis. NCT00004359.
22. Gordon KB, Chan LS, Woodley DT. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. British Journal of Dermatology 1997;136(3):415-20.
23. Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Archives of Dermatology 1990;126(3):339-50.
24. Hanson RD, Olsen KD, Rogers RS. Upper aerodigestive tract manifestations of cicatricial pemphigoid. The Annals Otology, Rhinology, and Laryngology 1988;97(5 Pt 1):493-9.
25. Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases [see comments]. British Journal of Dermatology 1999;140(5):865-74.
26. Ingen-Housz-Oro S, Prost-Squarcioni C, Pascal F, Doan S, Brette MD, Bachelez H, et al. Cicatricial pemphigoid: treatment with mycophenolate mofetil. Annales de Dermatologie et de Venereologie 2005;132:13-6.
27. Lamey PJ, Rees TD, Binnie WH, Rankin KV. Mucous membrane pemphigoid. Treatment experience at two institutions. Oral Surgery, Oral Medicine, and Oral Pathology 1992;74(1):50-3.
28. Letko E, Miserocchi E, Daoud YJ, Christen W, Foster CS, Ahmed AR. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clinical Immunology (Orlando, Fla) 2004;111:303-10.
29. Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 2004;111:1380-2.
30. Luke MC, Darling TN, Hsu R, Summers RM, Smith JA, Solomon BI, et al. Mucosal morbidity in patients with epidermolysis bullosa acquisita. Archives of Dermatology 1999;135(8):954-9.
31. Matthews RW, Pinkney RC, Scully C. The management of intransigent desquamative gingivitis with Dapsone. Annals of Dentistry 1989;48(1):41-3.
32. McCluskey P, Chang JH, Singh R, Wakefield D. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 2004;111:796-801.
33. McFadden JP, Leonard JN, Powles AV, Rutman AJ, Fry L. Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid. British Journal of Dermatology 1989;121(6):759-62.
34. Megahed M, Scharffetter-Kochanek K. Epidermolysis bullosa acquisita -successful treatment with colchicine. Archives of Dermatological Research 1994;286(1):35-46.
35. Mondino BJ. Cicatricial pemphigoid and erythema multiforme. Ophthalmology 1990;97(7):939-52.
36. Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. American Journal of Ophthalmology 1983;96(4):453-9.
37. Nayar M, Wojnarowska F. Cicatricial pemphigoid: a re-evaluation of therapy. The Journal of Dermatological Treatment 1993;4:89-93.
38. Poskitt L, Wojnarowska F. Minimizing cicatricial pemphigoid orodynia with minocycline. British Journal of Dermatology 1995;132:784-9.
39. Rappersberger K, Konrad K, Schenk P, Tappeiner G. [Acquired epidermolysis bullosa. A clinico-pathologic study]. Hautarzt 1988;39(6):355-62.
40. Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clinical and Experimental Dermatology 1998;23(6):254-7.
41. Rogers RS. Dapsone and sulfapyridine therapy of pemphigoid diseases. Australasian Journal of Dermatology 1986;27(2):58-63.
42. Rogers RS III, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. Journal of American Academy of Dermatology 1982;6(2):215-23.
43. Rogers RS III, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Seminars in Dermatology 1988;7(3):201-205.
44. Secchi AG, Tognon MS. Intraoperative mitomycin C in the treatment of cicatricial obliterations of conjunctival fornices. American Journal Ophthalmology 1996;122(5):728-30.
45. Foster CS, Neumann R, Tauber J. Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid. Documenta ophthalmologica. Advances in opthalmology 1992;82(3):223-9.
46. Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology 1991;98(6):858-62.
47. Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid [see comments]. Cornea 1991;10(3):185-95.
48. Thornhill M, Pemberton M, Buchanan J, Theaker E. An open clinical trial of sulphamethoxypyridazine in the treatment of mucous membrane pemphigoid. The British Journal of Dermatology 2000;143(1):117-26.
49. Vincent SD, Lilly GE, Baker KA. Clinical, historic, and therapeutic features of cicatricial pemphigoid. A literature review and open therapeutic trial with corticosteroids. Oral Surgery, Oral Medicine and Oral Pathology 1993;76(4):453-9.
50. Wright P. Enigma of ocular cicatricial pemphigoid. A comparative study of clinical and immunological findings. Transactions of the Ophthalmological Societies of the United Kingdom 1979;99(1):141-5.
51. Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group [see comments]. Archives of Dermatology 1995;131((1)):48-52.
52. Borradori L, Caldwell JB, Briggaman RA, Burr CE, Gammon WR, James WD, et al. Passive transfer of autoantibodies from a patient with mutilating epidermolysis bullosa acquisita induces specific alterations in the skin of neonatal mice. Archives of Dermatology 1995;131((5)):590-5.
53. Briggaman RA, Gammon WR, Woodley DT. Epidermolysis bullosa acquisita. In: Wojnarowska F, Briggaman RA editor(s). Management of blistering diseases. London: Chapman and Hall Medical, 1990:127-38.
54. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Archives of Dermatology 2002;138(3):370-9.
55. Dragan L, Eng AM, Lam S, Persson T. Tetracycline and niacinamide: treatment alternatives in ocular cicatricial pemphigoid. Cutis 1999;63(3):181-3.
56. Fine J. Cicatricial pemphigoid. In: Wojnarowska F, Briggaman RA editor(s). Management of blistering diseases. London: Chapman and Hall Medical, 1990:83-92.
57. Fivenson D, Breneman D, Rosen G, Hersh C, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Archives of Dermatology 1994;130(6):753-58.
58. Gammon WR, Briggaman RA, Inman AOd, Queen LL, Wheeler CE. Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. The Journal of Investigative Dermatology 1984;82(2):139-44.
59. Gammon WR. Epidermolysis bullosa acquisita. Seminars in Dermatology 1988;7((3)):218-24.
60. Kirtschig G. Autoantigens of cicatricial pemphigoid and their pathogenetic significance. Hautarzt 1998;49(11):818-25.
61. Lazarova Z, Yee C, Darling T, Briggaman RA, Yancey KB. Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. Journal of Clinical Investigation 1996;98(7):1509-18.
62. Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. The Journal of Clinical Investigation 1993;92(5):2480-8.
63. Wojnarowska F, Eady RAJ, Burge SM. Bullous eruptions. In: Champion RH, Burton JL, Burns DA, Breathnach SM editor(s). Textbook of Dermatology. 6th Edition. Vol. 3, Oxford: Blackwell Science Ltd., 1998:1873-1877, 1884-7.
64. Zillikens D, Wever S, Roth A, Hashimoto T, Brocker EB. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany [letter; comment]. Archives of Dermatology 1995;131(8):957-58.
65. Kirtschig G, Murrell DM, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Archives of Dermatology 2002;138(3):380-4.